Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health

Gary Golds,1 Devon Houdek,1 and Terra Arnason2

1Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada S7N 0W8
2Division of Endocrinology and Metabolism, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada S7N 0W8

Correspondence should be addressed to Terra Arnason; terra.arnason@usask.ca

Received 29 October 2016; Accepted 7 February 2017; Published 16 March 2017

Academic Editor: Neil Binkley

Copyright © 2017 Gary Golds et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

It is well recognized that bone loss accelerates in hypogonadal states, with female menopause being the classic example of sex hormones affecting the regulation of bone metabolism. Underrepresented is our knowledge of the clinical and metabolic consequences of overt male hypogonadism, as well as the more subtle age-related decline in testosterone on bone quality. While menopause and estrogen deficiency are well-known risk factors for osteoporosis in women, the effects of age-related testosterone decline in men on bone health are less well known. Much of our knowledge comes from observational studies and retrospective analysis on small groups of men with variable causes of primary or secondary hypogonadism and mild to overt testosterone deficiencies. This review aims to present the current knowledge of the consequences of adult male hypogonadism on bone metabolism. The direct and indirect effects of testosterone on bone cells will be explored as well as the important differences in male osteoporosis and assessment as compared to that in females. The clinical consequence of both primary and secondary hypogonadism, as well as testosterone decline in older males, on bone density and fracture risk in men will be summarized. Finally, the therapeutic options and their efficacy in male osteoporosis and hypogonadism will be discussed.

1. Introduction

Hypogonadism in adults is a well-acknowledged cause of overall bone loss and a contributor to the development of secondary osteoporosis. In female osteoporosis, bone loss has been well correlated to the declines in estrogen, generally following menopause. In normal male aging, a gradual decline in testosterone production can also occur with some older men developing late onset hypogonadism which is marked by significantly low testosterone levels and concurrent symptoms of hypogonadism. It seems reasonable to anticipate that low bioavailable levels of testosterone in aging men, similar to the decreased estrogen levels in menopause, would correlate to a loss in bone mineral density (BMD) and an increase in fracture risk. As expected, male hypogonadism is correlated with losses in bone quality, yet unexpectedly, the connection is not tightly dependent on testosterone levels. In general, it is not common to consider estrogen (E2) levels in men as contributing to bone health in men, yet the relative bioavailable E2 levels have the strongest correlation with maintenance of bone density. Nonetheless, hypogonadal men treated with testosterone do have statically significant gains in bone density over relatively short periods of time. To date, there have been limited studies, either clinical, in vitro, or in vivo, that specifically address the normal physiology of testosterone on the bone and the effect on bone quality in adult males in the presence of hypogonadism. As such, this review will focus on answering key questions regarding male hypogonadism as well as highlighting areas requiring further research and exploration. Specifically, we will address the following: What direct and indirect effects do testosterone, gonadotropins, and related hormones have on bone metabolism; what is the prevalence of male osteoporosis and what proportion arises from hypogonadism; what
are the clinical consequences of hypogonadism on bone quality and fracture risk; and how effectively can hormonal and/or other therapies reverse bone loss in men?

2. Definition and Epidemiology of Male Osteoporosis

2.1. How Do We Diagnose/Define Osteoporosis in Males?
Osteoporosis, as described by the World Health Organization (WHO) since 1994, is a condition characterized by low bone mass and microarchitectural bone deterioration that leads to bone fragility and fracture susceptibility [1]. In 1994, the WHO established diagnostic criteria for osteoporosis in postmenopausal females based on their bone mineral density (BMD) readings. They defined osteoporosis as the category in which individuals have a BMD standard deviation (SD) measurement, referred to as the T-score, of 2.5 or less below the norm established from their young adult female Caucasian reference population. Since then, the diagnostic criterion has been further refined by the WHO Collaborating Centre in 2007 who advocated for the comparative reference standard to be the BMD measured at the femoral neck (FN) using dual-energy X-ray absorptionmetry (DXA) and in comparison to Caucasian women aged 20–29 within the NHANES III database [2].

This updated reference standard has been accepted by a number of international organizations and authorities [3–6], yet many recognize that this Caucasian and female-only reference population is less than ideal for different ethnicities and male gender. Regarding male osteoporosis specifically, some organizations, including those in Canada, the USA, and Europe, have adopted the use of gender-specific reference populations [7, 8]. Ideally, in order to capture and acknowledge the differences in the peak BMD reference that occurs between males and females, the male peak BMD reference should be higher than that of females. Therefore, using a female-only reference underestimates the degree of male bone loss and by extension the diagnosis of osteoporosis [9–11]. However, studies have illustrated that despite this underestimation of the degree of deviation males have from a male reference norm, the fracture risk is the same between males and females for a given DXA BMD value and thus distinguishing the SD from a gender-specific reference is perhaps of little clinical significance [12–15]. Furthermore, the importance of BMD measurements has decreased as emphasis has shifted away from BMD measurements for diagnosis, and more towards the clinically significant fracture risk assessment, of which BMD measurements are only one of many factors that are now considered. For simplicity, it has been advocated by the WHO and others to use the traditional standard female-only reference population. Thus, regardless of whether one uses a female or male reference population, the traditional diagnostic category of BMD T-score SD ≤ −2.5 and between ≤1.0 and ≥2.5 is universally used to define osteoporosis and osteopenia in males aged ≥ 50, respectively. For individuals under age 50, the BMD Z-score, which uses an age- and a gender-specific reference, is used.

2.2. What Is the Prevalence of Male Osteoporosis and Hypogonadal-Related Osteoporosis?
Although the prevalence of osteoporosis amongst males ≥ 50 is significantly lower than the female population, male osteoporosis and osteopenia and its clinical consequences are significant. Though men tend to sustain osteoporotic fractures up to 10 years later in life than women, the mortality and morbidity associated with male hip fractures are higher than that of women, and men with known fragility fractures are less likely to receive treatment as compared to women [16]. Despite this, osteoporosis research has been highly female dominant, but an increasing awareness, insightful research, and greater appreciation of the importance of male bone quality continues to contribute to our understanding of male hypogonadal osteoporosis. The WHO has compiled data on the prevalence of male and female osteoporosis from different epidemiological studies around the world [1]. Their data is derived from the EVOS (European), CaMos (Canada), Rotterdam (Netherlands), Dubbo (Australia), Rochester (USA), and Hiroshima (Japan) studies. The pooled estimated prevalence of male osteoporosis is very low under age 70, yet rises significantly to an estimated prevalence of 22.6% in the very aged (>90 years old). A similar estimated prevalence of female osteoporosis reveals a significantly greater incidence for any age, including those under 70 years old (Table 1).

Epidemiological information on male osteoporosis arising from secondary causes, and male hypogonadism, specifically, is lacking, and therefore, the prevalence of male osteoporosis attributed to hypogonadism is unclear. The studies that have been done are few, involve a small number of centers, and have low patient numbers. The rate of identified secondary male osteoporosis (all causes) or osteoporosis-related fracture has been relatively consistent amongst multiple studies with ~50% having an attributable secondary cause for their osteoporosis [17–20]. Those few studies that reported the secondary causes for male osteoporosis have found rates ranging from 16 to 30% for hypogonadism as the attributable cause [18–22]. These small studies illustrate the high degree of identifiable causes of secondary male osteoporosis and the significant amount of hypogonadal-related male osteoporosis and osteoporosis-related fractures. These studies are however limited by their small sizes and fraught with all kinds of potential bias. Large studies are needed to better quantify the prevalence of secondary causes of male osteoporosis/osteopenia and osteoporosis-related fractures.

2.3. Are There Differences in the Architecture or Structure of Bone between Genders and Does This Impact Fracture Risk?
Given that the peak bone mass in males is higher than females, it is reasonable to expect that for a given BMD, males have a greater risk for fracture, as they have deviated further

Table 1: All cause prevalence of osteoporosis by age in men and women (from Kanis [2]).

| Age    | 50–60 | 60–70 | 70–80 | 80–90 | >90 |
|--------|-------|-------|-------|-------|-----|
| Male   | 0.6%  | 1.7%  | 4.3%  | 10.4% | 22.6% |
| Female | 3.4%  | 8.5%  | 19.2% | 37.3% | 61.3% |
Androgens have a direct role in bone marrow stromal cells (progenitors), and it is likely that blasts (bone deposition), osteoclasts (bone resorption), osteo-androgen receptor has been found to be expressed in osteo-development and maintenance is still being determined. The effect of sex steroids in bone function. It is also interesting to consider the type of bone loss during normal aging and how it compares between men and women. Healthy men possess a greater maximum degree of periosteal thickening than women that may contribute to the above-mentioned greater cortical thickness and cross-sectional diameter [23, 24, 26, 29, 32]. Therefore, males potentially enter age-related bone loss at an advantage. Interestingly, there are sex-related differences in the rate of age-related adverse effects on trabecular bone, where women lose both periosteal thickening and cortical thickness more rapidly than males [23, 24, 26, 29, 32]. The type of trabecular bone remodeling that occurs with aging also differs between the sexes, as males tend to have trabecular thinning and females tend to lose trabecular connectivity [23]. Therefore, despite the fact that males will have a larger deviation away from their gender-specific reference for any given DXA BMD value, this does not seem to translate into an increased fracture risk, and is perhaps related to the protective benefit of their peak bone characteristics, and different types of bone architectural changes with aging, as compared to females.

3. What Is the Normal Physiological Effect of Androgens on Bone Quality in Males?

3.1. Physiological Effect of Androgens and Their Receptors on Bone Metabolism. The exact role of testosterone on male bone development and maintenance is still being determined. The androgen receptor has been found to be expressed in osteoblasts (bone deposition), osteoclasts (bone resorption), osteocytes (bone homeostasis), and pluripotent mesenchymal bone marrow stromal cells (progenitors), and it is likely that androgens have a direct role in affecting the function of all of these bone-related cells and overall bone metabolism [33, 34]. Observational studies and case reports in patients with androgen insensitivity syndrome (AIS), where there is a partial or complete lack of androgen receptor signaling [35], have demonstrated reduced BMD in people with AIS, particularly in the lumbar spine and regardless of estrogen replacement [36–39]. This supports a direct role for androgen signaling and testosterone action in bone development and maintenance. Testosterone also contributes to indirect effects on bone through its conversion via aromatase to estrogen [40] as males with aromatase deficiency almost universally present with osteopenia or osteoporosis [41–44], and selective blockade of aromatase activity leads to decreased BMD in men [45, 46]. Taken together, it is likely that testosterone has direct effects on bone quality via the androgen receptor as well as indirect effects via conversion to estrogen by aromatase.

3.1.1. Limitations of Animal Models to Study Androgen Effects on Bone Health. Much of the knowledge available on the molecular and biochemical effects of androgens and estrogens on bone homeostasis comes from mouse models [33, 40]. However, caution must be used when extrapolating these results to humans. First of all, mice and rats lack sex hormone-binding globulin (SHBG) [47], which is the major serum-binding globulin to testosterone and estrogen. SHBG levels regulate the bioavailable levels of these hormones [48] as only estrogen and testosterone that is not bound to SHBG, but rather bound by albumin and other carrier proteins or is circulating freely, are considered available for biological signaling and activity [48]. The importance of SHBG in human bone health has been demonstrated by studies, which show that serum SHBG levels are inversely associated with BMD in both men and women [49, 50]. The lack of SHBG in rodents may also mean that rodents experience greater fluctuations in sex steroid levels, and these fluctuations in themselves may be important in regulating bone metabolism [40]. For example, in humans, parathyroid hormone (PTH) stimulates bone formation when given in a pulsatile fashion, whereas chronic exposure to PTH results in bone resorption. This demonstrates how pulsatile or intermittent surges of hormone levels may have different effects on bone function as compared to a more regulated chronic exposure to these same hormones. The levels of free estrogen in mice are also significantly lower when compared to humans which may suggest that localized metabolism of sex hormones in mice contribute more significantly to bone physiology in murine models as compared to humans. Models of primary hypogonadism utilizing orchietomy also result in the loss of other gonadal-specific hormones such as inhibin A which may also contribute to bone health [51]. Finally, global knockouts in mice of androgen or estrogen receptors lead to impairment of important negative regulation mechanisms outside of the bone itself which can lead to further derangement of hormone levels [52, 53]. Therefore, to best understand the specific effects of sex steroids on the bone, targeted knockouts in bone-specific cell lines such as osteoblasts, osteoclasts, and osteocytes should be used when trying to determine the role of sex steroids in bone function.

3.2. Direct Effects of Testosterone and the Androgen Receptor on Osteoblasts, Osteocytes, and Osteoclasts. Despite their limitations, mouse cell lines have provided insights into the role of testosterone in bone cells by generating cell line-specific knockouts of aromatase and the androgen receptor often by using Cre-Lox recombination technology. In osteoblasts, the loss of the androgen receptor resulted in decreases in trabecular bone mass, fewer trabeculae, and an increase in
trabecular separation with no effect on cortical bone [54–56]. This suggests that testosterone signaling through the androgen receptor in osteoblasts is important in trabecular but not cortical bone formation. This also suggests an important role of testosterone in contributing to bone strength and fracture risk as trabecular bone is an important determinant to both [57]. The direct role of testosterone in osteoclasts is less well established. We identified a single report using osteoclast-specific androgen receptor knockout mice, which reported no effect on bone mass in either male or female mice; however, full gene knockdown could not be confirmed, leaving these results in question [54]. This result is also somewhat surprising as it has also been found that there are an increased number of osteoclasts in the lumbar spine of these knockout mice [58, 59]. Overall, there needs to be further research done on the exact role of testosterone in osteocyte signaling and function.

Finally, osteocytes also express the androgen receptor and demonstrate increased androgen receptor expression with osteocyte differentiation suggesting a role for testosterone in their function [60]. Murine models with osteocyte-specific androgen receptor knockout have demonstrated decreased trabecular bone volume and trabecular number, and these decreases worsened with age [60]. Two additional mouse lines with osteocyte-specific androgen receptor knockout showed the role of the androgen receptor in prevention of age-related trabecular bone loss but not anabolic bone formation [61]. Overall this suggests that the androgen receptor in osteocytes is important for age-related prevention of trabecular bone resorption. In summary, testosterone likely has direct effects via the androgen receptor on osteoblasts by promoting trabecular bone formation and on osteocytes by preventing age-related resorption of trabecular bone. Further studies need to be conducted to fully elucidate any role of the androgen receptor in osteoclast function.

3.3. Indirect Effects of Testosterone via Aromatase Conversion to Estrogen. Testosterone can also have indirect effects in the body through its conversion to estrogen via aromatase. Given the expression of aromatase in human osteoblasts [62] and the common finding of osteopenia and osteoporosis in men with aromatase deficiency [44, 45], it is likely that aromatase has a significant contribution to bone structure in men. There is however limited data on the selective effects of aromatase on bone structure regardless of gender, with the majority of data coming from the overexpression of aromatase in mouse animal models. The overexpression of human aromatase in mouse osteoblasts led to animals with increased overall trabecular BMD, increased cortical BMD, increased cortical thickness, and a reduction in the number of osteoclasts [63]. A different study looked at the effect of global overexpression of human aromatase in mice and found that these animals had increased trabecular BMD, yet cortical bone effects were not analyzed in this study [64]. Confounding these results, however, was the simultaneous overall increase in testosterone and estrogen levels in these mice, making it hard to differentiate between the local effect of aromatase in the bone rather than the global effect of increased sex steroids. Overall, the specific role of aromatase on bone metabolism is an area that needs further study.

Taken altogether, testosterone likely has both direct effects on the bone via signaling through the androgen receptor in osteoblasts and osteocytes as well as indirect effects on the bone via aromatase activity in osteoblasts. Androgen receptor signaling in osteoblasts contributes to trabecular bone formation whereas androgens prevent osteocyte-mediated, age-related trabecular bone loss. Indirectly testosterone affects the bone through local conversion to estrogen by aromatase. This leads to both increased cortical and trabecular bone. This is not completely surprising as aromatase activity should increase local estrogen levels, and male estrogen receptor knockout mice have similarly decreased trabecular and cortical bone development and maintenance [65, 66].

4. The Effect of Male Hypogonadism on Bone Quality and Fracture Risk

4.1. What is the Correlation between BMD and Fracture Rate to Circulating Levels of Testosterone, SHBG, and Estrogen? The precise role of testosterone in the maintenance of bone health and conversely the contribution that low testosterone has to the development of male osteoporosis are still not entirely clear. A number of observational trials have been done to investigate potential risk factors for osteoporosis in men. One of the largest is the osteoporotic fractures in men study (MrOS), which followed thousands of men over the age of 65 in Sweden, the United States, and Hong Kong for an average of 4.5 years (Table 2). The initial results of the Sweden cohort of MrOS found that free testosterone levels were positively correlated with BMD in the hip, femur, and arm but not the lumbar spine. Lower levels of free testosterone were also correlated with increased fracture risk [67]. Estrogen levels were positively correlated with BMD in all locations including the lumbar spine [67]. However, further data analysis using multivariate analysis in the same cohort later found that only bioavailable estrogen (BioE2) and SHBG but not testosterone were independently associated with fracture risk [68]. The Hong Kong cohort of the MrOS trial found that only BioE2 was significantly associated with BMD, whereas the levels of SHBG and free testosterone had a nonsignificant correlation with BMD [49]. In terms of fracture risk, neither testosterone nor estrogen levels were predictive of risk, though patients with both low testosterone and low estrogen were at the greatest risk of fracture overall suggesting a combined role of both hormones [49].

The MrOS study also had a North American study group looking at American men over the age of 65, but its results differed slightly from the Hong Kong and Swedish cohorts. Estrogen levels, but not testosterone, exhibited a significant correlation with BMD with the lowest BioE2 levels exhibiting the highest loss of BMD over the study period. SHBG was also negatively associated with BMD and perhaps reflects the free testosterone availability, as SHBG is the major serum-binding partner for testosterone. Finally, men with a combination of low free testosterone and low BioE2 and also men with high SHBG had the highest overall risk of fracture [50]. The overall results of the MrOS suggested that BioE2 is definitively associated with both BMD and fracture risk in
Table 2: Comparison of BMD and fracture risk associations of sex steroids and SHBG from large studies.

| Study       | Characteristics                          | Testosterone | Fracture risk | SHBG | Testosterone | BMD | Estrogen | SHBG |
|-------------|------------------------------------------|--------------|---------------|------|--------------|-----|----------|------|
|             |                                          | H V O        | H V O         | H V O| H V O        | H V O|
| CHAMP       | Observational study 958 Australian men over 70 5-year follow-up | N – N N N N Y Y Y Y Y – – Y – – | | | | |
| Dubbo       | Observational study 609 Australian men over 60 Average follow-up of 5.8 years | Y N N N N N – – – – N* N* – Y Y Y Y Y Y* | | | | |
| LASA        | Observational study 623 Dutch men over 55 Follow-up 3–6 years | – – N – – Y – – – Y – – Y – – – – – | | | | |
| Tromsø      | Observational study 3564 Norwegian men and women aged 25 to 84 (avg age 60) Average follow-up of 6.5 years | – – – – – – – – – – Y* – – Y* – – Y | | | | |
| Framingham  | Prospective cohort study 405 men aged 68 to 96 Hypogonadal men (testosterone < 3 ng/mL) versus eugonadal men | – N N Y Y Y Y Y Y N Y – – – – – – – – | | | | |
| mROS Sweden | Observational study 3014 Swedish men aged 69–80 Average follow-up of 3.32 years | N N N Y Y Y Y Y Y N Y – – – – – – – – | | | | |
| mROS US     | Observational study 1234 men over 65 Average follow-up of 4.6 years | – – – – – – – – – N – – Y – – Y – – | | | | |
| mROS US     | Observational study 1436 American men over 65 Average follow-up of 4.7 years | N – N N Y Y Y Y Y N Y – – – – – – – – | | | | |
| mROS Hong Kong | Observational study 1498 men over 65 from Hong Kong Average follow-up of 4 years | N – N N Y Y N N N Y N Y N – – N | | | | |
| Rotterdam   | Prospective case-control study 179 men over 55 from Rotterdam Average follow-up of 6.5 years | – – – N – – N – – – – – – Y* – – N* | | | | |
| EPIC-Oxford | Prospective cohort study 155 men from Oxford avg age 51 6-year follow-up period | – – N – – Y – – – N – – – – – – – – | | | | |

Y denotes statistically significant association; N denotes no association; – indicates not studied. H = hip, V = vertebral, and O = other sites not including hip or vertebral. * represents analysis was only univariate and not multivariate.
eldestly men. SHBG is also associated with fracture risk and very likely associated with BMD, while free testosterone is not clearly associated with BMD but may have some role in fracture risk in elderly men. It is important to note that the study population in MrOS, regardless of the country of original, reflects a spectrum of hypogonadal states from normal to below normal. This is likely a true reflection of the events associated with age-related testosterone decline in men and allows for extrapolations for predicted effects on bone quality in elderly men with a range of testosterone levels from normal to true hypogonadism.

A number of studies similar to MrOAS have also provided conflicting data on the role of testosterone in male bone health. One study looking at a subgroup from the Framingham cohort looked at the fracture risk in men that were hypogonadal (serum testosterone < 3 ng/mL) as compared to eugonadal men. Men with the highest estradiol levels had the highest BMD, and those with the lowest estradiol levels had the highest risk of hip fracture. There was no difference in BMD or hip fracture risk in hypogonadal men compared to eugonadal men, suggesting no significant role of testosterone in bone health [69]. This role of estrogen and lack of a role of testosterone supports the findings of the MrOS study. Other studies looking for correlations between the development of male osteoporosis and testosterone levels give conflicting results. Australian men in the Dubbo study (>60 years old) were found to have decreased BMD associated with low BioE2 and testosterone levels, but only low testosterone and not estrogen was associated with increased fracture risk, particularly at the hip [70]. Results from the Tromsø study failed to demonstrate any correlation between changes in BMD and estrogen or testosterone levels in men, though high SHBG was significantly associated with lower BMD but was noted to have little role on its overall variance based on predictive models [71]. Finally, the MINOS study once again found that only estrogen, and not lower levels of testosterone, was positively associated with BMD in elderly men. They did note that hypogonadal men had increased rates of falls and markers of bone resorption [72].

4.2. Bone Mineral Density, Bone Turnover, and Response to Testosterone Therapy in Young Hypogonadal Men. While these previous studies enrolled large numbers of elderly men, they tend to not look specifically at hypogonadism, but rather overall testosterone levels and how it relates to BMD and fracture risk. For example, in the MrOS study, only men in the lowest testosterone quartile examined would possibly have testosterone levels low enough to meet a clinical diagnosis of hypogonadism. Additionally, the few subjects that would meet the criteria for hypogonadism likely had late onset hypogonadism related to age-related testosterone decline, which is a distinct entity from primary or secondary hypogonadism in younger males [88–90]. Therefore, while useful in suggesting a role of testosterone in osteoporotic fractures in men combined with proven increased fracture risk in men undergoing androgen deprivation, it seems likely that low testosterone is indeed associated with fracture risk in older men.

5. Comparison of Bone Quality between Hypergonadotropic and Hypogonadotropic Hypogonadism in Men

5.1. Does Bone Density Differ in Primary versus Central (Pituitary and Hypothalamic) Hypogonadal States? Interestingly, there is some evidence that men with secondary or central hypogonadism (hypogonadotropic hypogonadism) in fact have lower baseline BMD compared to men with primary hypogonadism (hypergonadotropic hypogonadism). Primary hypogonadism is associated with marked elevations of FSH and LH, whereas pituitary or hypothalamic
dysfunction results in inappropriately low levels of these two hormones [101–104]. This difference in BMD is somewhat counterintuitive as many people with primary hypogonadism such as Klinefelter’s syndrome would be hypogonadal even during pubertal bone development which can cause an overall decrease in the development of peak bone mass [105], and pituitary dysfunction commonly presents after puberty is completed. Assuming there is no bias within these studies for the frequency of pubertal hypogonadism, the reason for men with secondary hypogonadism to have lower BMD compared to those with primary hypogonadism is not clear. One could speculate that LH or FSH may have protective effects on bone which would be lost in secondary hypogonadism, yet studies have found that FSH stimulates osteoclast activity [106], and in both women and men, higher FSH levels are correlated with decreased BMD [107–110]. Similarly, higher levels of LH seem to be negatively correlated with BMD in women [111] and men [110]. Therefore, a lack of FSH or LH in secondary hypogonadism does not explain a more significant loss of BMD compared to men with primary hypogonadism.

Primary hypogonadism arising from testicular failure also differs from secondary hypogonadism in that additional testosterone-derived hormones may be specifically lacking, as compared to hypogonadism arising from pituitary/hypothalamic dysfunction. It may be that there are specific factors produced by the gonads that inhibit bone formation, which would then be absent in primary hypogonadism, explaining why men with secondary hypogonadism seem to have more significant declines in BMD as compared to men with primary hypogonadism. However, known gonad-specific hormones, such as inhibin A and insulin-like factor 3, are actually known to positively contribute to BMD, making this explanation unlikely [51, 112]. Further research should be done to confirm if men with secondary hypogonadism do indeed have worse BMD compared to those with primary hypogonadism and why this may be the case.

5.2. Are There Clinical Differences between Fracture Risk, Fracture Site, and Degree of Bone Loss between Primary and Central Hypogonadism? The differences in BMD between primary hypogonadism and secondary hypogonadism suggest that the type of hypogonadism may affect the overall risk of osteoporosis and fragility fracture. Currently, there is a limited amount of data on the effects of different types of hypogonadism on BMD and fracture risk. There are several unique patient populations in both primary hypogonadism (Klinefelter’s syndrome, testicular failure from surgery, or chemotherapy) and secondary hypogonadism (opiate abuse, prolactinomas) for which there is data on BMD and fracture risk.

Individuals with primary hypogonadism due to Klinefelter syndrome consistently present with lower BMD compared to that of age-matched controls [113–119], though two smaller studies did not demonstrate any difference in BMD [98, 120]. The decreases in BMD were most typically seen in the lumbar spine and femoral neck. The effect of orchiectomy is less well studied, but patients receiving orchiectomy have higher rates of osteoporosis and osteopenia compared to population controls, and low testosterone levels in these patients were significantly associated with lower BMD [121, 122].

In men with central hypogonadism from pituitary prolactinomas (and the resulting repression of FSH and LH), BMD is frequently found to be reduced to either the osteopenic or osteoporotic range (55% overall) [123–125], with an associated increase in vertebral fracture risk [126]. Interestingly, it was the lack of estrogen, but not testosterone, that was associated with decreased BMD in men with prolactinomas [123, 124]. Patients with idiopathic hypogonadotrophic hypogonadism have been found to have universally lower BMD compared to age-matched controls, though no data for possible increased fracture risk was found [94, 95, 98, 104, 116, 127, 128]. Chronic opiate use can also lead to central hypogonadism, and patients on long-term opiates have higher rates of osteopenia and osteoporosis, decreased BMD, and increased fracture risk [129–131]. However, there are multiple potential contributors to decreased BMD and increased fractures in this population, though lower BMD was found to be associated with lower testosterone levels in one study [131]. Other causes of hypogonadism and their potential effects on BMD and fracture risk have not yet been studied. Overall, there is limited data on how specific types of male hypogonadism contribute to BMD and fracture risk, though there is a significant trend for men with hypogonadism to have decreased BMD.

6. Treatment Options and Responses in Male Hypogonadal Osteoporosis

6.1. What Is the Benefit of Testosterone Replacement on BMD and Fracture Risk in Men with Osteoporosis and Hypogonadism? Treatment for symptomatic hypogonadal males to improve their symptoms and enhance BMD has been recommended in North America by the Endocrine Society and appears in their 2010 clinical guidelines [132]. Additionally, the 2012 Endocrine Society Osteoporosis in Men guideline also recommends the use of testosterone therapy in men with symptomatic low testosterone who are at high risk of fracture [133] though this should be done in combination with a medication with a proven antifracture effect such as a bisphosphonate. It has been well known that testosterone treatment in hypogonadal males has beneficial effects on BMD, but unfortunately to date, no studies have adequately assessed its clinical impact on fracture risk [132, 133]. Despite the known ability of testosterone to improve BMD in hypogonadal males, testosterone treatment is not recommended to enhance BMD unless they truly have symptomatic hypogonadism. The reasoning at this time is that the potential risks of testosterone therapy (including acne, erythrocytosis, prostate abnormalities, formulation-specific adverse effects, and potential negative sleep apnea and cardiovascular effects) outweigh the benefit to BMD enhancement [132].

There have been a number of small, randomized controlled studies evaluating the effect in men of testosterone treatment on the bone, regardless of underlying testosterone levels, which generally demonstrated improvements to BMD. Hoppèa et al. [134] reviewed 14 of these randomized
controlled trials (RCT) of testosterone treatment in males, all of which looked at BMD at the lumbar spine and femoral head, without fracture risk outcomes. Regarding the lumbar spine BMD, only 5 of the 14 showed significant increases, with the remaining showing nonsignificant (6 of 14) or no (3 of 14) differences after therapy. Considering the femoral head, measureable gains were detected in 9 of 14, yet most were nonsignificant differences. These results must be interpreted with caution due to the clear limitations of these studies, including small study sizes ($n=30$–223), variable follow-up (6–36 months), and great heterogeneity in study population characteristics including such key considerations as age, baseline androgen levels, and dosing/choice of testosterone delivery. Despite these limitations and variations in outcome results, the authors concluded that there was sufficient evidence to suggest, at the least, a benefit in lumbar spine BMD with testosterone therapy. The Endocrine Society came to the same conclusion and incorporated this into their 2010 guideline publication regarding testosterone treatment in hypogonadal males [132].

Since this 2013 review by Hoppéa et al., there have been additional studies in specific male populations that have provided further evidence for the potential benefit of testosterone treatment on lumbar spine and femoral BMD increases. Permpongkosol et al. [135] published a 2016 observational study of testosterone treatment in 120 late-onset hypogonadal males with a mean age of 65.6 years, representing the decline in gonadal testosterone in older men. These participants were treated with intramuscular testosterone injections for 5 to 8 years, the longest study to date. Significant increases in BMD at both the lumbar and femoral neck sites were detected. Interestingly, there was a differential rate of BMD response to therapy between the hip and the spine: significant BMD increases at the femoral neck were not detected until after 48 months of treatment, as opposed to 24 months for significant changes at the lumbar spine. This difference between changes in the femoral neck and spine may be explained by the different contribution of cortical and trabecular bone in these two regions. Vertebrae are comprised of approximately 75% trabecular bone, whereas the femoral head is only 50% trabecular bone [136]. This relatively greater effect of testosterone on trabecular bone structures such as the spine would also be keeping with the greater effect of testosterone on trabecular bone in mouse models. In terms of testosterone side effects, PSA, prostate volume, and hematocrit were found to significantly increase with treatment.

Wang et al. [137] published a two-year open label RCT of 186 hypogonadal males aged ≥60 with osteoporosis at baseline. The three study arms included oral low dose testosterone treatment, oral standard dose testosterone treatment, and placebo. BMD was assessed intermittently and significant increases in the BMD at the lumbar spine and femoral neck became apparent after 6 months and 12 months in standard dose and low dose testosterone treatment, respectively. These gains remained significant throughout the remainder of the 24-month study. Prior to 18 months, the standard dose treatment gains were significantly greater than the lower dose, but after 18 months of therapy, there was no significant difference between the two groups. Prostate size and PSA levels were monitored but showed no significant differences between study groups.

Bouloux et al. [138] published a one-year double-blinded RCT in 2013 involving 322 hypogonadal males aged ≥50. The four study arms included testosterone therapy with oral low dose, intermediate dose, and high dose testosterone treatment versus placebo. Significant BMD increases were detected the earliest (12 months) and over dispersed body sites (lumbar spine, total hip, trochanter, and intertrochanteric) only for the highest testosterone doses. In contrast, at the 12-month point, the intermediate dose group demonstrated significant BMD increases only for trochanter and intertrochanteric sites. Adverse effects were not analyzed.

A final study by Rodriguez-Tolra et al. [139] is a two-year prospective treatment study involving testosterone therapy in 50 hypogonadal males aged ≥50. Patients were treated with topical testosterone gel for the first 12 months, followed by testosterone intramuscular injection for the remaining 12 months. It is not rationalized why a 12-month period of topical treatment followed by a 12-month period of intramuscular treatment was used. Significant improvements were found in lumbar spine BMD at both 12 and 24 months, total hip and trochanter at 24 months only, and no significant changes for the femoral neck. Of note, hematocrit and PSA levels increased significantly from baseline over the 24 months of treatment.

Although these more recent studies provide further evidence for the anabolic effects of testosterone replacement on lumbar BMD, and also demonstrate improvements of BMD at the femoral site, one great limitation is the lack of clinical determination of fracture rate. Also, the variable rates for adverse effects of testosterone leave the issue of patient risk benefit still up for debate. While testosterone replacement is known to potentially cause erythrocytosis as well as growth of metastatic or subclinical prostate cancer [132], the risk of testosterone therapy in men with heart failure, obstructive sleep apnea, or lower urinary tract symptoms has recently been called into question [140]. Furthermore, controversy remains over the potential risk of testosterone therapy on cardiovascular mortality, though a clear reproducible cardiovascular risk has yet to be demonstrated [140]. There remains the need for larger, longer, multicenter RCTs that evaluate both the change in BMD and fracture incidence for testosterone treatment in hypogonadal males. In addition, subgroup analysis is needed to characterize the relationship of benefit with severity of testosterone deficiency, degree of baseline BMD loss, and the dose of testosterone replacement.

### 6.2. What Is the Role for Bisphosphonate Treatment in Male Hypogonadal-Related Osteoporosis? The indications for bisphosphonate treatment in males are the same as for females. The 2012 male Osteoporosis Guidelines from the Endocrinology Society has recommended bisphosphonate, or the alternative Denosumab, and also Teriparatide in select populations, to improve BMD and fracture risk for all men aged 50 and older with a spine or hip fragility fracture, osteoporosis, or osteopenia with a high calculated fracture
risk [133]. Regardless of whether males are hypogonadal or not, if they fulfill any of these above indications, treatment is recommended.

The benefit for bisphosphonate therapy in the hypogonadal male population is largely extrapolated from these benefits observed in the general male population. There have been a number of studies looking at bisphosphonate treatment for those individuals undergoing androgen deprivation therapy for prostate cancer, which show significant BMD protection during treatment [141–144]. However, it would be difficult to justify extrapolating this data to hypogonadal males with established BMD deficits. A single small (n = 22, age 29–69) RCT considered the effect of bisphosphonate treatment in a purely hypogonadal population of men, with proven osteoporosis or osteopenia and long-standing hypogonadism on testosterone replacement over three years [145]. Their treatment arms consisted of Alendronate versus placebo for one year followed by Alendronate in both for the next two years. Within 1 year, significant improvements in BMD occurred at both the lumbar and femoral neck sites. Following the transition to equal Alendronate treatment, lumbar BMD appeared to plateau with no significant improvement in BMD while the femoral neck BMD continued to improve. It is difficult to draw conclusions from a small single center study like this, but as described in the sections to follow, some of the male osteoporosis RCTs did subgroup analysis of low testosterone groups and found equal benefit [146, 147]. Additional larger RCTs in hypogonadal populations are needed to not only confirm the benefits of bisphosphonate treatment but to help quantify its impact and how it compares to male osteoporosis in general.

Gradually over time, RCTs have emerged in the general male population and demonstrate clear benefits of bisphosphonate therapy on BMD and fracture risk [148, 149]. There have been a number of male bisphosphonate RCTs since the beginning of 2000 that have demonstrated a unanimous improvement in BMD as well as a number of them showing a benefit in fracture risk reduction [146, 147, 150–153]. Regardless of the bisphosphonate used, or 1 versus 2 years of follow-up, all trials found significant improvement in lumbar and femoral BMD measurements over the 1–2 years of study. Fractures were also reduced with bisphosphonate therapy, with significant reductions in radiographic vertebral fractures [147, 150, 151], and significant reduction in both vertebral and nonvertebral radiographic fractures [153].

Considering male hypogonadism and bisphosphonate responses by the bone, few studies performed testosterone level subgroup analysis. Orwell et al. [147] found no difference in lumbar BMD improvements between normal and low testosterone subgroups but did not comment on femoral BMD or fracture incidence. Boonen et al. [152] found a greater degree of BMD improvement in males with lower baseline testosterone.

6.3. What Evidence Supports Testosterone and Bisphosphonate Combination Treatment for Male Osteoporosis? The Endocrinology Society, in their 2012 guidelines, recommends combination therapy with bisphosphonate, or equivalent options, and testosterone replacement only in symptomatic hypogonadal males with indications for pharmacological treatment [133]. There have been no specific RCTs published looking at dual therapy in this population; rather the recommendation stems from the known benefit of both studied in isolation. The impact of the two head-to-head and in combination is not known. Thus, symptomatic hypogonadal males with spine or hip fragility fracture, osteoporosis, or osteopenia with a high calculated fracture risk have indication for testosterone treatment by virtue of their hypogonadal symptoms and have indication for bisphosphonates by virtue of their BMD and fracture risk.

6.4. What Is the Evidence for Denosumab or Teriparatide Treatment in Male Osteoporosis? There have been no RCTs of Denosumab or Teriparatide therapy involving hypogonadal males with osteoporosis or osteopenia. There have been some studies showing the benefit of Denosumab and Teriparatide on BMD in the male population in general [154–158]. Teriparatide has also been observed to show significant reduction in vertebral fractures in males [159]. Denosumab has only shown a significant reduction in vertebral fractures when used in males receiving androgen deprivation therapy [160]. As a result of these findings, the Endocrinology Society has supported the use of Denosumab in the context of androgen deprivation therapy, as an alternative to bisphosphonate therapy in males with indications for treatment [133]. The efficacy of Denosumab and Teriparatide in the hypogonadal male population is yet to be studied.

7. Conclusions

Testosterone has a clear direct effect on bone health. Testosterone signaling stimulates osteoblasts to form trabecular bone and helps osteocytes prevent trabecular bone loss. This leads to the decreased BMD and increased fracture risk seen in men with both primary and secondary hypogonadism. Testosterone also has indirect effects on bone through its aromatization to estrogen via aromatase. The role of testosterone in the bone health of elderly men is less clear but likely reduces fracture risk and may potentially contribute to BMD and bone health via aromatization, as estrogen is clearly associated with both fracture risk and BMD in elderly men. Bisphosphonates should be first-line therapy in the treatment of male hypogonadism-related osteoporosis, with the consideration for the addition of testosterone replacement therapy. Other pharmacological therapies specifically for male osteoporosis secondary to hypogonadism have yet to be studied.

Additional Points

**Key Points.** (1) Female reference populations for bone mineral densities remain an acceptable standard for males aged ≥50, yet there is an increasing worldwide use of male reference populations. (2) The prevalence of male osteoporosis and hypogonadal-related osteoporosis increases with age yet remains lower than females of similar ages. (3) Male hypogonadism results in declines of bone density and is correlated with increased fracture risk, yet estrogen plays
the largest role in bone loss and fracture risk in older men. (4) Hypogonadotropic hypogonadism appears to correlate with lower bone quality than hypergonadotropic hypogonadism for unclear reasons. (5) Testosterone replacement therapy can effectively reverse hypogonadism-induced bone loss in men, yet bisphosphonates are considered first-line treatment for established osteoporosis in asymptomatic males. (6) Testosterone signaling through the androgen receptor promotes trabecular bone formation in osteoblasts and inhibits trabecular bone loss through osteocytes but has a largely unknown effect on osteoclasts.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Gary Golds and Devon Houdek contributed equally to the manuscript.

References

[1] World Health Organization, “Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group,” World Health Organization Technical Report Series, vol. 843, pp. 1–129, 1994.

[2] J. A. Kanis, “Assessment of osteoporosis at the primary health-care level,” WHO Collaborating Centre, University of Sheffield, Sheffield, UK, 2007.

[3] A. Papaioannou, S. Morin, A. M. Cheung et al., “2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary,” Canadian Medical Association Journal, vol. 182, no. 17, pp. 1864–1873, 2010.

[4] National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, “British Orthopaedic Association, British Society of Rheumatology, National Osteoporosis Society, Osteoporosis 2000, Osteoporosis Dorset, Primary Care Rheumatology Society, Royal College of Physicians and Society for Endocrinology, Osteoporosis. Clinical Guideline for Prevention and Treatment, Executive Summary,” 2016, https://www.shef.ac.uk/NOGG/NOGG_Executive_Summary.pdf.

[5] J. A. Kanis and C. C. Gluer, “An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation,” Osteoporosis International, vol. 11, no. 3, pp. 192–202, 2000.

[6] J. A. Kanis, N. Burlet, C. Cooper et al., “European guidance for the diagnosis and management of osteoporosis in post-menopausal women,” Osteoporosis International, vol. 19, no. 4, pp. 399–428, 2008.

[7] F. Cosman, S. J. de Beur, M. S. LeBoff et al., “Clinician’s guide to prevention and treatment of osteoporosis,” Osteoporosis International, vol. 25, no. 10, pp. 2359–2381, 2014.

[8] International Society of Clinical Densitometry, “2015 ISCD official positions—adult,” 2015, http://www.iscd.org/official-positions/2015-iscd-official-positions-adult/.

[9] E. O. Kenneth Faulkner, “Implications in the use of T-scores for the diagnosis of osteoporosis in men,” Journal of Clinical Densitometry, vol. 5, no. 1, pp. 87–93, 2002.

[10] A. C. Looker, E. S. Orwoll, C. C. Johnston Jr. et al., “Prevalence of low femoral bone density in older U.S. adults from NHANES III,” Journal of Bone and Mineral Research, vol. 12, no. 11, pp. 1761–1768, 1997.

[11] C. Berger, D. Goltzman, L. Langsetmo et al., “Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis,” Journal of Bone and Mineral Research, vol. 25, no. 9, pp. 1948–1957, 2010.

[12] J. A. Kanis, E. V. McCloskey, H. Johansson, A. Oden, L. J. Melton III, and N. Khaltava, “A reference standard for the description of osteoporosis,” Bone, vol. 42, no. 3, pp. 467–475, 2008.

[13] P. L. Selby, M. Davies, and J. E. Adams, “Do men and women fracture bones at similar bone densities?” Osteoporosis International, vol. 11, no. 2, pp. 153–157, 2000.

[14] M. Lunt, D. Felsenberg, J. Reeve et al., “Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS study,” Journal of Bone and Mineral Research, vol. 12, no. 11, pp. 1883–1894, 1997.

[15] C. E. De Laet, B. A. Van Hout, H. Burger, A. E. Weel, A. Hofman, and H. A. Pols, “Hip fracture prediction in elderly men and women: validation in the Rotterdam study,” Journal of Bone and Mineral Research, vol. 13, no. 10, pp. 1587–1593, 1998.

[16] J. M. Kaufman, J. Y. Register, S. Boonen et al., “Treatment of osteoporosis in men,” Bone, vol. 53, no. 1, pp. 134–144, 2013.

[17] S. R. Pye, K. R. Adams, J. P. Halsey et al., “Frequency and causes of osteoporosis in men,” Rheumatology (Oxford), vol. 42, no. 6, pp. 811–812, 2003.

[18] C. S. Ryan, V. I. Petkov, and R. A. Adler, “Osteoporosis in men: the value of laboratory testing,” Osteoporosis International, vol. 22, no. 6, pp. 1845–1853, 2011.

[19] S. P. Baillie, C. E. Davison, F. J. Johnson, and R. M. Francis, “Pathogenesis of vertebral crush fractures in men,” Age and Ageing, vol. 21, no. 2, pp. 139–141, 1992.

[20] N. Kelepouris, K. D. Harper, F. Gannon, F. S. Kaplan, and J. G. Haddad, “Severe osteoporosis in men,” Annals of Internal Medicine, vol. 123, no. 6, pp. 452–460, 1995.

[21] H. K. Kamel, “Male osteoporosis: new trends in diagnosis and therapy,” Drugs & Aging, vol. 22, no. 9, pp. 741–748, 2005.

[22] J. A. Jackson and M. Kleerekoper, “Osteoporosis in men: diagnosis, pathophysiology, and prevention,” Medicine (Baltimore), vol. 69, no. 3, pp. 137–152, 1990.

[23] J. K. Lambert, M. Zaidi, and J. I. Mechanick, “Male osteoporosis: epidemiology and the pathogenesis of aging bones,” Current Osteoporosis Reports, vol. 9, no. 4, pp. 229–236, 2011.

[24] E. Seeman, “Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities,” The American Journal of Medicine, vol. 95, no. 5, pp. 225–285, 1993.

[25] M. Biggemann, D. Hilweg, and P. Brinckmann, “Prediction of the compressive strength of vertebral bodies of the lumbar spine by quantitative computed tomography,” Skeletal Radiology, vol. 17, no. 4, pp. 264–269, 1988.

[26] L. Moskilde and L. Moskilde, “Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals,” Bone, vol. 11, no. 2, pp. 67–73, 1990.

[27] M. L. Bouxsein, L. J. Melton III, B. L. Riggs et al., “Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT,”
B. A. Christiansen, D. L. Kopperdahl, D. P. Kiel, T. M. Keaveny, and M. L. Bouxsein, "Mechanical contributions of the cortical and trabecular compartments contribute to differences in age-related changes in vertebral body strength in men and women assessed by QCT-based finite element analysis," *Journal of Bone and Mineral Research*, vol. 26, no. 5, pp. 974–983, 2011.

Y. Duan, T. J. Beck, X. F. Wang, and E. Seeman, "Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging," *Journal of Bone and Mineral Research*, vol. 18, no. 10, pp. 1766–1774, 2003.

B. L. Riggs, L. J. Melton III, R. A. Robb et al., "Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites," *Journal of Bone and Mineral Research*, vol. 19, no. 12, pp. 1945–1954, 2004.

P. Szulc, F. Munoz, F. Duboeuf, F. Marchand, and P. D. Delmas, "Low width of tubular bones is associated with increased risk of fragility fracture in elderly men—the MINOS study," *Bone*, vol. 38, no. 4, pp. 595–602, 2006.

C. R. Russo, F. Lauretani, E. Seeman et al., "Structural adaptations to bone loss in aging men and women," *Bone*, vol. 38, no. 1, pp. 112–118, 2006.

M. Sinnesael, F. Claessens, S. Boonen, and D. Vanderschueren, "Novel insights in the regulation and mechanism of androgen action on bone," *Current Opinion in Endocrinology, Diabetes, and Obesity*, vol. 20, no. 3, pp. 240–244, 2013.

B. Noble, J. Routledge, H. Stevens, I. Hughes, and W. Jacobson, "Androgen receptors in bone-forming tissue," *Hormone Research*, vol. 51, no. 1, pp. 31–36, 1999.

M. P. Meng, D. Kadokoro-Cuccaro, T. Bunch, and I. A. Hughes, "Androgen insensitivity syndrome," Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 29, no. 4, pp. 569–580, 2015.

T. S. Han, D. Goswami, S. Trikudanathan, S. M. Creighton, and G. S. Conway, "Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis," *European Journal of Endocrinology*, vol. 159, no. 2, pp. 179–185, 2008.

D. L. Danilovic, P. H. Correa, E. M. Costa, K. F. Melo, B. B. Mendonca, and I. J. Arnhold, "Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene," *Osteoporosis International*, vol. 18, no. 3, pp. 369–374, 2007.

V. Sobel, B. Schwartz, Y. S. Zhu, J. J. Cordero, and J. Imperato-McGinley, "Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes," *The Journal of Clinical Endocrinology and Metabolism*, vol. 91, no. 8, pp. 3017–3023, 2006.

R. Marcus, D. Leary, D. L. Schneider, E. Shane, M. Favus, and C. A. Quigley, "The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome," *The Journal of Clinical Endocrinology and Metabolism*, vol. 85, no. 3, pp. 1032–1037, 2000.

D. Vanderschueren, M. R. Laurent, F. Claessens et al., "Sex steroid actions in male bone," *Endocrine Reviews*, vol. 35, no. 6, pp. 906–960, 2014.
male mice,” *Journal of Bone and Mineral Research*, vol. 24, no. 4, pp. 621–631, 2009.

[57] L. Dalle Carbonare and S. Giannini, “Bone microarchitecture as an important determinant of bone strength,” *Journal of Endocrinological Investigation*, vol. 27, no. 1, pp. 99–105, 2004.

[58] K. Rana, R. A. Davey, and J. D. Zajac, “Human androgen deficiency: insights gained from androgen receptor knockout mouse models,” *Asian Journal of Andrology*, vol. 16, no. 2, pp. 169–177, 2014.

[59] T. Sato, T. Matsumoto, H. Kawano et al., “Brain masculinization requires androgen receptor function,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 6, pp. 1673–1678, 2004.

[60] M. Sinnesael, F. Claessens, M. Laurent et al., “Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes,” *Journal of Bone and Mineral Research*, vol. 27, no. 12, pp. 2535–2543, 2012.

[61] K. M. Wren, X. W. Zhang, D. A. Olson, R. T. Turner, and U. T. Iwaniec, “Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes,” *Bone*, vol. 51, no. 5, pp. 835–846, 2012.

[62] H. Sasano, M. Uzuki, T. Sawai et al., “Aromatase in human bone tissue,” *Journal of Bone and Mineral Research*, vol. 12, no. 9, pp. 1416–1423, 1997.

[63] K. Sjögren, M. Lagerquist, S. Moverare-Skrtic et al., “Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects,” *Journal of Bone and Mineral Research*, vol. 24, no. 7, pp. 1263–1270, 2009.

[64] Z. Peng, X. Li, S. Mäkelä, H. K. Viäännén, and M. Poutanen, “Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase,” *Journal of Bone and Mineral Research*, vol. 19, no. 8, pp. 1320–1328, 2004.

[65] O. Vidal, M. K. Lindberg, K. Hollberg et al., “Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 10, pp. 5474–5479, 2000.

[66] L. Vandenput, S. Boonen, E. Van Herck, J. V. Swinnen, R. Bouillon, and D. Vanderschueren, “Evidence from the aged orchidectomized rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than Salpha-dihydrotestosterone,” *Journal of Bone and Mineral Research*, vol. 17, no. 11, pp. 2080–2086, 2002.

[67] D. Mellström, O. Johnell, O. Ljunggren et al., “Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden,” *Journal of Bone and Mineral Research*, vol. 21, no. 4, pp. 529–535, 2006.

[68] D. Mellström, L. Vandenput, H. Mallmin et al., “Older men with low serum estradiol and high serum SHBG have an increased risk of fractures,” *Journal of Bone and Mineral Research*, vol. 23, no. 10, pp. 1552–1560, 2008.

[69] S. Amin, Y. Zhang, C. T. Sawin et al., “Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study,” *Annals of Internal Medicine*, vol. 133, no. 12, pp. 951–963, 2000.

[70] C. Meier, T. V. Nguyen, D. J. Handelsman et al., “Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study,” *Archives of Internal Medicine*, vol. 168, no. 1, pp. 47–54, 2008.

[71] A. Bjørnerem, N. Emaus, G. K. Berntsen et al., “Circulating sex steroids, sex hormone-binding globulin, and longitudinal changes in forearm bone mineral density in postmenopausal women and men: the Tromsø study,” *Calcified Tissue International*, vol. 81, no. 2, pp. 65–72, 2007.

[72] P. Szulc, B. Claustrat, F. Marchand, and P. D. Delmas, “Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 88, no. 11, pp. 5240–5247, 2003.

[73] T. W. Auyeung, J. S. Lee, T. Kwok et al., “Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men,” *European Journal of Endocrinology*, vol. 164, no. 5, pp. 811–817, 2011.

[74] M. T. Drake, M. H. Murad, K. F. Mauck et al., “Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 97, no. 6, pp. 1861–1870, 2012.

[75] T. S. Tran, J. R. Center, M. J. Seibel et al., “Relationship between serum testosterone and fracture risk in men: a comparison of RIA and LC-MS/MS,” *Clinical Chemistry*, vol. 61, no. 9, pp. 1182–1190, 2015.

[76] H. L. Stanley, B. P. Schmitt, R. M. Poses, and W. P. Deiss, “Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men?” *The American Geriatrics Society*, vol. 39, no. 8, pp. 766–771, 1991.

[77] J. Torremadé-Barreda, J. Rodríguez-Tolrà, I. Román-Romera, A. Padró-Miquel, J. Rius-Moreno, and E. Franco-Miranda, “Testosterone-deficiency as a risk factor for hip fracture in elderly men,” *Actas Urologicas Españolas*, vol. 37, no. 3, pp. 142–146, 2013.

[78] O. Risto, E. Hammar, K. Hammar, M. Fredriksson, M. Hammar, and O. Wahlström, “Elderly men with a history of distal radius fracture have significantly lower calcaneal bone density and free androgen index than age-matched controls,” *The Aging Male*, vol. 15, no. 1, pp. 59–62, 2012.

[79] S. P. Tuck, A. C. Scane, W. D. Fraser, M. J. Diver, R. Eastell, and R. M. Francis, “Sex steroids and bone turnover markers in men with symptomatic vertebral fractures,” *Bone*, vol. 43, no. 6, pp. 999–1005, 2008.

[80] N. O. Kuchuk, N. M. van Schoor, S. M. Pluijm, J. H. Smit, W. de Ronde, and P. Lips, “The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women,” *Clinical Endocrinology*, vol. 67, no. 2, pp. 295–303, 2007.

[81] A. W. Roddam, P. Appleby, R. Neale et al., “Association between endogenous plasma hormone concentrations and fracture risk in men and women: the EPIC-Oxford prospective cohort study,” *Journal of Bone and Mineral Metabolism*, vol. 27, no. 4, pp. 485–493, 2009.

[82] B. Hsu, M. J. Seibel, R. G. Cumming et al., “Progressive temporal change in serum SHBG, but not in serum testosterone or estradiol, is associated with bone loss and incident fractures in older men: the Concord Health and Ageing in Men Project,” *Journal of Bone and Mineral Research*, vol. 31, no. 12, pp. 2115–2122, 2016.

[83] E. Orwell, L. C. Lambert, L. M. Marshall et al., “Endogenous testosterone levels, physical performance, and fall risk in
older men,” Archives of Internal Medicine, vol. 166, no. 19, pp. 2124–2131, 2006.

[84] L. Vandenput, F. Labrie, D. Mellström et al., “Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men,” Journal of Bone and Mineral Research, vol. 22, no. 2, pp. 220–227, 2007.

[85] A. Wang, Z. Obertová, C. Brown et al., “Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand,” BMC Cancer, vol. 15, no. 1, Article no. 837, 2015.

[86] M. R. Smith, W. C. Lee, J. Brandman, Q. Wang, M. Botteman, and C. L. Pashos, “Gonadotropin-releasing hormone antagonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7897–7903, 2005.

[87] M. R. Smith, S. P. Boyce, E. Moyneur, M. S. Duh, M. K. Raut, and J. Brandman, “Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer,” The Journal of Urology, vol. 175, no. 1, pp. 136–139, 2006.

[88] A. B. Araujo and G. A. Wittert, “Andropause in the aging male,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 25, no. 2, pp. 303–319, 2011.

[89] G. Corona, G. Rastrelli, and M. Maggi, “Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 27, no. 4, pp. 557–579, 2013.

[90] I. Huhtaniemi and G. Forti, “Male late-onset hypogonadism: pathogenesis, diagnosis and treatment,” Nature Reviews Urology, vol. 8, no. 6, pp. 335–344, 2011.

[91] L. Katznelson, J. S. Finkelstein, D. A. Schoenfeld, D. I. Rosenthal, E. J. Anderson, and A. Klibanski, “Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism,” The Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 12, pp. 4358–4365, 1996.

[92] K. Ishizaka, M. Suzuki, Y. Kageyama, K. Kihara, and K. Yoshida, “Bone mineral density in hypogonadal men remains low after long-term testosterone replacement,” Asian Journal of Andrology, vol. 4, no. 2, pp. 117–121, 2002.

[93] J. Bobjer, K. Bogeors, S. Isaksson et al., “High prevalence of hypogonadism and associated impaired metabolic and bone mineral status in subfertile men,” Clinical Endocrinology, vol. 85, no. 2, pp. 189–195, 2016.

[94] C. X. Li, S. T. Tang, and Q. Zhang, “Changes in bone mineral density and metabolic parameters after pulsatile gonadorelin treatment in young men with hypogonadotropic hypogonadism,” International Journal of Endocrinology, vol. 2015, Article ID 324524, 5 pages, 2015.

[95] E. M. Laitinen, M. Hero, K. Vaaraahiti, J. Tommiska, and T. Raivio, “Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism,” International Journal of Andrology, vol. 35, no. 4, pp. 534–540, 2012.

[96] P. Deb, S. K. Gupta, and M. M. Godbole, “Effects of short-term testosterone replacement on aereal bone mineral density and bone turnover in young hypogonadal males,” Indian Journal of Endocrinology and Metabolism, vol. 16, no. 6, pp. 947–951, 2012.

[97] J. Vieira da Costa, J. F. Pereira-Lima, and M. da Costa Oliveira, “Bone mineral density in early-onset hypogonadism and the effect of hormonal replacement,” Journal of Clinical Densitometry, vol. 7, no. 3, pp. 334–340, 2004.

[98] M. De Rosa, L. Paesano, V. Nuzzo et al., “Bone mineral density and bone markers in hypogonadotropic hypogonadal men after prolonged testosterone treatment,” Journal of Endocrinological Investigation, vol. 24, no. 4, pp. 246–252, 2001.

[99] S. J. Howell, J. A. Radford, J. E. Adams, and S. M. Shalet, “The impact of mild Leydig cell dysfunction following cytokotoxic chemotherapy on bone mineral density (BMD) and body composition,” Clinical Endocrinology, vol. 52, no. 5, pp. 609–616, 2000.

[100] D. Canale, E. Vignali, F. Golia, E. Martino, A. Pinchera, and C. Marcocci, “Effects of hormonal replacement treatment on bone mineral density and metabolism in hypogonadal patients,” Molecular and Cellular Endocrinology, vol. 161, no. 1-2, pp. 47–51, 2000.

[101] M. Schubert, C. Bullmann, T. Minnemann, C. Reiners, W. Krone, and F. Jockenhövel, “Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism,” Hormone Research, vol. 60, no. 1, pp. 21–28, 2003.

[102] A. Gioia, L. Ceccoli, V. Ronconi et al., “Vitamin D levels and bone mineral density: are LH levels involved in the pathogenesis of bone impairment in hypogonadal men?” Journal of Endocrinological Investigation, vol. 37, no. 12, pp. 1225–1231, 2014.

[103] E. Leifke, H. C. Körner, T. M. Link, H. M. Behre, P. E. Peters, and E. Nieschlag, “Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men,” European Journal of Endocrinology, vol. 138, no. 1, pp. 51–58, 1998.

[104] H. M. Behre, S. Kiesch, E. Leifke, T. M. Link, and E. Nieschlag, “Long-term effect of testosterone therapy on bone mineral density in hypogonadal men,” The Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 8, pp. 2386–2390, 1997.

[105] D. Fintini, A. Grossi, C. Brufani et al., “Bone mineral density and body composition in male children with hypogonadism,” Journal of Endocrinological Investigation, vol. 32, no. 7, pp. 585–589, 2009.

[106] L. Sun, Y. Peng, A. C. Sharrow et al., “FSH directly regulates bone mass,” Cell, vol. 125, no. 2, pp. 247–260, 2006.

[107] M. R. Sowers, G. A. Greendale, I. Bondarenko et al., “Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN,” Osteoporosis International, vol. 14, no. 3, pp. 191–197, 2003.

[108] Z. R. Xu, A. H. Wang, X. P. Wu et al., “Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women,” Clinica Chimica Acta, vol. 400, no. 1-2, pp. 8–13, 2009.

[109] M. Zaidi, L. Sun, P. Liu et al., “Pituitary-bone connection in skeletal regulation,” Hormone Molecular Biology and Clinical Investigation, vol. 28, no. 2, pp. 85–94, 2016.

[110] B. Hsu, R. G. Cumming, M. J. Seib et al., “Reproductive hormones and longitudinal change in bone mineral density and incident fracture risk in older men: the Concord Health
and Aging in Men Project,” *Journal of Bone and Mineral Research*, vol. 30, no. 9, pp. 1701–1708, 2015.

[111] J. A. Blair, R. Palm, J. Chang et al., “Luteinizing hormone downregulation but not estrogen replacement improves ovariectomized-associated cognition and spine density loss independently of treatment onset timing,” *Hormones and Behavior*, vol. 78, pp. 60–66, 2016.

[112] S. Overvad, K. Bay, A. Bojesen, and C. H. Gravholt, “Low INS3 in Klinefelter syndrome is related to osteocalcin, testosterone treatment and body composition, as well as measures of the hypothalamic–pituitary–gonadal axis,” *Andrologia*, vol. 2, no. 3, pp. 421–427, 2014.

[113] V. V. Shanhogue, S. Hansen, N. R. Jørgensen, K. Brixen, and C. H. Gravholt, “Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in Klinefelter syndrome,” *Journal of Bone and Mineral Research*, vol. 29, no. 11, pp. 2474–2482, 2014.

[114] D. G. Jo, H. S. Lee, Y. M. Joo, and J. T. Seo, “Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome,” *Yonsei Medical Journal*, vol. 54, no. 6, pp. 1331–1335, 2013.

[115] A. Ferlin, M. Schipilliti, C. Vinanzi et al., “Bone mass in subjects with Klinefelter syndrome: role of testosterone levels and androgen receptor gene CAG polymorphism,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 96, no. 4, pp. E739–E745, 2011.

[116] H. R. Choi, S. K. Lim, and M. S. Lee, "Site-specific effect of testosterone on bone mineral density in male hypogonadism," *Journal of Korean Medical Science*, vol. 10, no. 6, pp. 431–435, 1995.

[117] A. Ferlin, R. Selice, A. Di Mambro et al., “Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome,” *Osteoporosis International*, vol. 26, no. 8, pp. 2193–2202, 2015.

[118] A. Bojesen, N. Birkebæk, K. Kristensen et al., “Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone,” *Osteoporosis International*, vol. 22, no. 5, pp. 1441–1450, 2011.

[119] A. Ferlin, M. Schipilliti, A. Di Mambro, C. Vinanzi, and C. Foresta, “Osteoporosis in Klinefelter’s syndrome,” *Molecular Human Reproduction*, vol. 16, no. 6, pp. 402–410, 2010.

[120] S. Hiéronimus, V. Lussiez, F. Le Duff, P. Ferrari, B. Bstärdig, and P. Fénichel, “Klinefelter’s syndrome and bone mineral density: is osteoporosis a constant feature?” *Annales d’Endocrinologie*, vol. 72, no. 1, pp. 14–18, 2011.

[121] M. Ondrusova, D. Ondrus, L. Dusek, and B. Spanikova, “DAMAGE of hormonal function and bone metabolism in long-term survivors of testicular cancer,” *Neoplasma*, vol. 56, no. 6, pp. 473–479, 2009.

[122] M. Ondrusova, B. Spanikova, K. Sevcikova, and D. Ondrus, “Testosterone deficiency and bone metabolism damage in testicular cancer survivors,” *American Journal of Men’s Health*, 2016.

[123] G. Mazzotti, T. Porcelli, M. Mormando et al., “Vertebral fractures in males with prolactinoma,” *Endocrine*, vol. 39, no. 3, pp. 288–293, 2011.

[124] E. C. Naliato, M. L. Farias, G. R. Braucks, F. S. Costa, D. Zylberberg, and A. H. Violante, “Prevalence of osteopenia in men with prolactinoma,” *Journal of Endocrinological Investigation*, vol. 28, no. 1, pp. 12–17, 2005.

[125] S. L. Greenspan, R. M. Neer, E. C. Ridgway, and A. Klibanski, “Osteoporosis in men with hyperprolactinemia hypogonadism,” *Annals of Internal Medicine*, vol. 104, no. 6, pp. 777–782, 1986.

[126] P. Vestergaard, J. O. Jørgensen, C. Hagen et al., “Fracture risk is increased in patients with GH deficiency or untreated prolactinomas—a case–control study,” *Clinical Endocrinology*, vol. 56, no. 2, pp. 159–167, 2002.

[127] J. S. Finkelstein, A. Klibanski, R. M. Neer, S. L. Greenspan, D. I. Rosenthal, and W. F. Crowley, “Osteoporosis in men with idiopathic hypogonadotropic hypogonadism,” *Annals of Internal Medicine*, vol. 106, no. 3, pp. 354–361, 1987.

[128] G. Iolascon, L. Frizzi, M. Bianco et al., “Bone involvement in males with Kallmann disease,” *Aging Clinical and Experimental Research*, vol. 27, supplement 1, pp. S31–S36, 2015.

[129] T. W. Kim, D. P. Alford, A. Malabanan, M. F. Holick, and J. H. Samet, “Low bone density in patients receiving methadone maintenance treatment,” *Drug and Alcohol Dependence*, vol. 85, no. 3, pp. 258–262, 2006.

[130] P. Vestergaard, L. Rejnmark, and L. Mosekilde, “Fracture risk associated with the use of morphine and opiates,” *Journal of Internal Medicine*, vol. 260, no. 1, pp. 76–87, 2006.

[131] F. Gotthardt, C. Huber, C. Thierfelder et al., “Bone mineral density and its determinants in men with opioid dependence,” *Journal of Bone and Mineral Metabolism*, vol. 35, no. 1, pp. 99–107, 2016.

[132] S. Bhasin, G. R. Cunningham, F. J. Hayes et al., “Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 6, pp. 2536–2559, 2010.

[133] N. B. Watts, R. A. Adler, J. P. Bilezikian et al., “Osteoporosis in men: an Endocrine Society clinical practice guideline,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 97, no. 6, pp. 1802–1822, 2012.

[134] E. Hoppéa, B. Bouvard, M. Royer, D. Chappard, M. Audrana, and E. Legrand, “Is androgen therapy indicated in men with osteoporosis?” *Joint, Bone, Spine*, vol. 80, no. 5, pp. 459–465, 2013.

[135] S. Permpongkosol, K. Khupulsup, S. Leelaphiwat, S. Pavavattananusorn, S. Thongpradit, and T. Petchthong, “Effects of 8 year treatment of long-acting testosterone undecanoate therapy on bone mineral density, microarchitecture, the key to bone quality,” *Osteoporosis International*, vol. 24, no. 6, pp. 1159–1167, 2013.

[136] M. L. Brandi, “Microarchitecture, the key to bone quality,” *Rheumatology (Oxford)*, vol. 48, supplement 4, pp. iv3–iv8, 2009.

[137] Y. J. Wang, J. K. Zhan, W. Huang et al., “Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone,” *International Journal of Endocrinology*, vol. 2013, Article ID 570413, p. 6, 2013.

[138] P. M. Bouloux, J. J. Legros, J. M. Elbers et al., “Testosterone deficiency syndromes: an *Annals of Internal Medicine*, vol. 85, no. 3, pp. 258–262, 2006.
[139] J. Rodriguez-Tolra, J. Torremade, S. di Gregorio, L. Del Rio, and E. Franco, "Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome," Andrologia, vol. 1, no. 4, pp. 570–575, 2013.

[140] A. D. Seftel, M. Kathrins, and C. Niederberger, "Critical update of the 2010 Endocrine Society clinical practice guidelines for male hypogonadism: a systematic analysis," Mayo Clinic Proceedings, vol. 90, no. 8, pp. 1104–1115, 2015.

[141] M. R. Smith, J. Eastham, D. M. Gleason, D. Shasha, S. Tchekmedjian, and N. Zinner, "Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer," The Journal of Urology, vol. 169, no. 6, pp. 2008–2012, 2003.

[142] J. M. Lang, M. Wallace, J. T. Becker et al., "A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy," Clinical Genitourinary Cancer, vol. 11, no. 4, pp. 407–415, 2013.

[143] J. W. Denham, M. Nowitz, D. Joseph et al., "Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer," BJU International, vol. 114, no. 12, pp. 334–335, 2014.

[144] M. R. Smith, F. J. McGovern, A. L. Zietman et al., "Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer," The New England Journal of Medicine, vol. 345, no. 13, pp. 948–955, 2001.

[145] I. Shimon, V. Eshed, R. Doolman, B. A. Sela, A. Karasik, and I. Vered, "Alendronate for osteoporosis in men with androgen-repleted hypogonadism," Osteoporosis International, vol. 16, no. 12, pp. 1591–1596, 2005.

[146] S. Boonen, J. Y. Reginster, J. M. Kaufman et al., "Fracture risk and zoledronic acid therapy in men with osteoporosis," The New England Journal of Medicine, vol. 367, no. 18, pp. 1714–1723, 2012.

[147] E. Orwoll, M. Ettinger, S. Weiss et al., "Alendronate for the treatment of osteoporosis in men," The New England Journal of Medicine, vol. 343, no. 9, pp. 604–610, 2000.

[148] R. A. Adler, "Osteoporosis in men: a review," Bone Research, vol. 2, Article ID 14001, 2014.

[149] A. Herrera, A. Lobo-Escolar, J. Mateo, J. Gil, E. Ibarz, and L. Gracia, "Male osteoporosis: a review," World Journal of Orthodontics, vol. 3, no. 12, pp. 223–234, 2012.

[150] E. S. Orwoll, N. C. Binkley, E. M. Lewiecki, U. Gruntmanis, M. A. Fries, and G. Dasic, "Efficacy and safety of monthly ibandronate in men with low bone density," Bone, vol. 46, no. 4, pp. 970–976, 2010.

[151] J. D. Ringe, H. Faber, P. Farahmand, and A. Dorst, "Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1 year study," Rheumatology International, vol. 26, no. 5, pp. 427–431, 2006.

[152] S. Boonen, E. S. Orwoll, D. Wenderoth, K. J. Stoner, R. Eusebio, and P. D. Delmas, "Once-weekly risedronate in men with osteoporosis: results of a 2 year, placebo-controlled, double-blind, multicenter study," Journal of Bone and Mineral Research, vol. 24, no. 4, pp. 719–725, 2009.

[153] J. D. Ringe, P. Farahmand, H. Faber, and A. Dorst, "Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2 year study," Rheumatology International, vol. 29, no. 3, pp. 311–315, 2009.

[154] R. Niimi, T. Kono, A. Nishihara et al., "Analysis of daily teriparatide treatment for osteoporosis in men," Osteoporosis International, vol. 26, no. 4, pp. 1303–1309, 2015.

[155] E. S. Orwoll, W. H. Scheele, S. Paul et al., "The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis," Journal of Bone and Mineral Research, vol. 18, no. 1, pp. 9–17, 2003.

[156] E. Orwoll, C. S. Teglbjaerg, B. L. Langdahl et al., "A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density," The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 9, pp. 3161–3169, 2012.

[157] T. Nakamura, T. Matsumoto, T. Sugimoto et al., "Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)," The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 7, pp. 2599–2607, 2014.

[158] B. L. Langdahl, C. S. Teglbjaerg, P. R. Ho et al., "A 24 month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial," The Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 4, pp. 1335–1342, 2015.

[159] J. M. Kaufman, E. Orwoll, S. Goemaere et al., "Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy," Osteoporosis International, vol. 16, no. 5, pp. 510–516, 2005.

[160] M. R. Smith, B. Egerdie, N. Hernandez Toriz et al., "Denosumab in men receiving androgen-deprivation therapy for prostate cancer," The New England Journal of Medicine, vol. 361, no. 8, pp. 745–755, 2009.